Grit Zahn

Biography

Head of research, Eternygen >15 years in pharmaceutical drug development Former positions: From 2000-2010 she worked at Jerini AG, a Germany based pharmaceutical company which recently approved the drug Firazyr for the treatment of the orphan disease hereditary angioedema and was acquired by Shire plc. for € 330 mio. She holds several positions with leading responsibilities at the biology and screening department including Senior Director Lead Discovery Biology. She was also involved in starting Jerini Ophthalmic Inc, New York US. 2011-2013 she worked at ipal GmbH, the technology transfer and commercialization company of all Berlin Universities. She was head of Project Management R&D and responsible for the evaluation, development and commercialization of early innovative technologies in the area of Life Science in particular drug development with investments of the Technology Development Fund of the Investment Bank Berlin (IBB). Grit Zahn started her career at Charité University Hospital in Berlin in the field of antibody engineering, molecular libraries and molecular evolution. She holds a PhD in Biochemistry from Humboldt University Berlin, Germany. > 2 years research and development on INDY

Research Interest

Head of research, Eternygen >15 years in pharmaceutical drug development Former positions: From 2000-2010 she worked at Jerini AG, a Germany based pharmaceutical company which recently approved the drug Firazyr for the treatment of the orphan disease hereditary angioedema and was acquired by Shire plc. for € 330 mio. She holds several positions with leading responsibilities at the biology and screening department including Senior Director Lead Discovery Biology. She was also involved in starting Jerini Ophthalmic Inc, New York US. 2011-2013 she worked at ipal GmbH, the technology transfer and commercialization company of all Berlin Universities. She was head of Project Management R&D and responsible for the evaluation, development and commercialization of early innovative technologies in the area of Life Science in particular drug development with investments of the Technology Development Fund of the Investment Bank Berlin (IBB). Grit Zahn started her career at Charité University Hospital in Berlin in the field of antibody engineering, molecular libraries and molecular evolution. She holds a PhD in Biochemistry from Humboldt University Berlin, Germany. > 2 years research and development on INDY